Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40213 | 1.00 | HTR2A (0.53) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL23044637 | 1.00 | HTR2A (0.53) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL12082016 | 1.00 | HTR2A (0.53) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL30233044 | 1.00 | HTR2A (0.53) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL409084 | 0.96 | HTR2A (0.56) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL125510 | 0.93 | HTR2A (0.56) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL10062010 | 0.93 | HTR2A (0.56) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL30232973 | 0.89 | BCL9 (0.57) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL916518 | 0.89 | BCL9 (0.57) | HTR2ABCL9CTNNB1MAPTGAA | |
| SCHEMBL409598 | 0.88 | HTR2A (0.59) | HTR2ABCL9CTNNB1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| CN-112442011-B | Prodrug compound and application thereof in treating cancers | 润佳（苏州）医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4021912-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| WO-2021035360-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-04 | — | — | WO | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9951183-B2 | Amphiphilic blockcopolymers comprising reduction sensitive biodegradable polyesteramides | DSM IP ASSETS, B.V. (NL) | 2018-04-24 | — | — | US | disclosed |
| US-20170281785-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NOVO NORDISK A/S (DK) | 2017-10-05 | — | — | US | disclosed |
| US-20170218123-A1 | AMPHIPHILIC BLOCKCOPOLYMERS COMPRISING REDUCTION SENSITIVE BIODEGRADABLE POLYESTERAMIDES | DSM IP ASSETS, B.V. (NL) | 2017-08-03 | — | — | US | disclosed |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-5907068-A | TRIFLUOROMETHYLSUBSTITUTED COMPOUND INCLUDED IN PEPTIDES | ZENECA INC. (US) | 1999-05-25 | — | — | US | disclosed |
| US-5726158-A | INHIBITORS OF HUMAN LEUKOCYTE ELASTASE USEFUL IN TREATING TISSUE DEGENERATIVE DISEASES; TRIFLUOROMETHYL KETONE SUBSTITUTED DI-, TRI-, AND TETRA-PEPTIDE DERIVATIVES | ZENECA INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5414132-A | Peptide intermediates | ZENECA INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5194588-A | Inhibitors of human leukocyte elastase, di-, tri- and tetra-peptides | ICI AMERICAS INC. (US) | 1993-03-16 | — | — | US | disclosed |
| EP-0189305-B1 | PEPTIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| US-5055450-A | Di-, tri- and tetrapeptides as inhibitors of human leukocyte elastase | ICI AMERICAS INC. (US) | 1991-10-08 | — | — | US | disclosed |
| US-4910190-A | Containing a nitrogen containing heterocycle ring structure | ICI AMERICAS INC. (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | ABL1, FLT3, SRC | HTR2A 4073/4885BCL9 849/4885CTNNB1 3582/4885 |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | HTR2A 4424/4885BCL9 2662/4885CTNNB1 4715/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | HTR2A 4308/4885BCL9 361/4885CTNNB1 1180/4885 |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | CSF3R, GMFG, GALNT1 | HTR2A 4836/4885BCL9 1798/4885CTNNB1 4874/4885 |
| US-20170281785-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | HTR2A 4652/4885BCL9 2105/4885CTNNB1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.